Breakthrough Oral Drug Delivery Technology Enables Depression Treatment Through Fat Absorption Pathways
核心洞察
Monash University and Seaport Therapeutics (搜索) developed GlyphAllo (搜索)™, an oral formulation of allopregnanolone that bypasses liver metabolism by mimicking dietary fat absorption.
Phase 2a clinical trials demonstrated the drug significantly reduced salivary cortisol levels (p=0.0001) compared to placebo in stress response testing.
The Glyph™ platform technology transforms injectable neurosteroids into oral medications, with a Phase 2b trial (BUOY-1) currently evaluating GlyphAllo (搜索) for major depressive disorder (搜索).
Researchers at Monash University and Seaport Therapeutics (搜索) have achieved a significant breakthrough in drug delivery technology, developing an oral formulation of the neurosteroid allopregnanolone that leverages natural fat absorption pathways to overcome previous limitations requiring intravenous administration. The research, published in Science Translational Medicine, presents the first clinical evidence that their fat-modified drug GlyphAllo (搜索)™ can achieve therapeutically relevant levels in human bloodstream.
Revolutionary Drug Delivery Approach
The innovative Glyph™ platform addresses a longstanding challenge in pharmaceutical development by chemically linking drugs to fat molecules, effectively "tricking" the digestive system into treating medications like dietary nutrients. Professor Christopher Porter, Director of the Monash Institute of Pharmaceutical Sciences and senior author of the study, explained the mechanism: "The lymphatic system is a remarkably efficient conduit for absorbing and transporting dietary fats. By altering drugs to mimic these materials, we effectively trick the digestive system into treating the drug like a key nutrient, allowing it to skirt the metabolic processes in the liver and enter the bloodstream through a back door."
Traditional oral delivery of allopregnanolone has been severely limited by first-pass metabolism, where the liver breaks down the drug before it can reach therapeutic targets. "The liver acts in many ways like a master security guard for the body, assessing anything that enters from the gut. Some drugs are let through, but for others, like allopregnanolone, the liver breaks them down before they can ever reach the brain," Porter noted.
Clinical Trial Results Demonstrate Efficacy
The technology's translation to humans was validated through Phase 1 and Phase 2a clinical trials in healthy volunteers. In Phase 1 studies, GlyphAllo (搜索) was generally well tolerated across single and multiple-ascending oral doses ranging from 70-1000 mg, providing therapeutically relevant plasma exposures of allopregnanolone.
The Phase 2a proof-of-concept trial utilized the Trier Social Stress Test, a validated clinical model of anxiety (搜索), to assess the drug's pharmacodynamic effects. A single 375 mg dose of GlyphAllo (搜索) significantly reduced salivary cortisol levels compared to placebo (p=0.0001), demonstrating the drug's ability to potently blunt acute physiological stress responses.
Advancing Treatment for Major Depressive Disorder
The promising clinical results have positioned GlyphAllo (搜索) as a compelling candidate for treating major depressive disorder (搜索) (MDD). Seaport Therapeutics (搜索) launched a global, randomized, double-blind, placebo-controlled Phase 2b trial called BUOY-1 in July, currently evaluating the drug in adults with MDD, with or without anxious distress.
The development represents a transformative advancement for allopregnanolone, a well-established neurosteroid with clinically validated antidepressant, anti-anxiety (搜索), and sleep-promoting effects that previously required administration as a 60-hour intravenous infusion. "For many years, the therapeutic potential of allopregnanolone has been restricted by the need to administer as a long 60-hour intravenous infusion, but this technology finally unlocks its potential as an accessible daily treatment," Porter stated.
Broader Platform Applications
Beyond neuropsychiatry applications, the Glyph platform demonstrates potential for transforming drug delivery across multiple therapeutic areas. Dr. Michael Chen, Co-Founder and Chief Scientific Officer at Seaport Therapeutics (搜索) and senior author of the paper, emphasized the technology's versatility: "Importantly, these findings also further validate the broad compatibility of the Glyph platform to transform promising small molecules with pharmacokinetic limitations into prodrugs with the right properties to address those challenges with potential applications extending beyond neuropsychiatry into oncology, immunology and inflammation, metabolic disease, and obesity."
The research collaboration involved teams from Monash University's Drug Delivery, Disposition and Dynamics Theme, led by Professor Porter with co-authors Professor Natalie Trevaskis and multiple research scientists, working alongside Seaport Therapeutics (搜索) researchers including Dr. Jamie Simpson, Dr. Daniel Bonner, Dr. Steven Paul, Dr. Michael Chen, and Dr. Tim Quach.